1.	Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC) Phase: Phase IV Type: Treatment Status: Closed Age: Not specified Sponsor: Other Protocol IDs: HSC-MS-06-0478, OSP-24412, NCT00581425
2.	Phase II/III Randomized Study of CDDP/5-FU vs CDDP/5-FU/IFN-A for Metastatic Pancreatic Cancer (Summary Last Modified 02/95) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: under 75 Sponsor: Protocol IDs: EORTC-40924
3.	Phase II/III Randomized Study of Interleukin-2 and Interferon alfa With Versus Without Fluorouracil for Metastatic Renal Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 79 Sponsor: Protocol IDs: FRE-FNCLCC-95009, EU-96026
4.	Phase II/III Randomized Study of SCH 54031 (Polyethylene Glycol Interferon alfa-2b) Versus Interferon alfa-2b in Patients With Newly Diagnosed Chronic Phase Myelogenous Leukemia (Summary Last Modified 01/2000) Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: SPRI-C98-026, SPRI-C98-026-054, SPRI-I98-026
5.	Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 19 and over Sponsor: Other Protocol IDs: 01-002-0601, NCT00205751
6.	ABR-217620 With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 06762004, NCT00420888
7.	Phase III Randomized Study of IFN-A with vs without 13-CRA in Patients with Metastatic Renal Cell Carcinoma (Summary Last Modified 02/96) Phase: Phase III Type: Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: MSKCC-94004, E-2894, NCI-T93-0198D, T93-0198
8.	Phase III Randomized Study of Standard Therapy with ABCM (DOX/BCNU/CTX/L-PAM) vs Intensive Therapy with C-VAMP (CTX/VCR/DOX/MePRDL) Followed by High-Dose L-PAM (with or without TBI) with Hematopoietic Rescue, Both with IFN-A Maintenance, for Previously Untreated Myeloma (Summary Last Modified 03/2001) Phase: Phase III Type: Treatment Status: Closed Age: under 65 Sponsor: Protocol IDs: MRC-LEUK-MYEL-VII, EU-94030, NCT00002599
9.	Phase III Randomized Study of Maintenance Therapy with IFN-A vs Placebo for Intermediate- and High-Grade non-Hodgkin's Lymphoma in Complete or Partial Remission Following Salvage Chemotherapy (Summary Last Modified 03/1999) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SPRI-C94-105/I94-105, SCH-C94-105, SCH-I94-105, NCI-V95-0665
10.	Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Other Protocol IDs: EORTC-30951, NCT00002737
11.	High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Phase: Phase III Type: Treatment Status: Closed Age: 16 to 75 Sponsor: Other Protocol IDs: CDR0000064718, EORTC-18952, NCT00002763
12.	Phase III Randomized Study of Immunotherapy with an Allogeneic Melanoma Vaccine plus Interferon Alfa vs Interferon Alfa Alone in Patients with Metastatic Malignant Melanoma (Summary Last Modified 04/2000) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CORIXA-2885-14, RIR-2885-14, YALE-HIC-8666, NCI-V96-0883, NCT00002767
13.	Phase III Randomized Study of Consolidation and Maintenance Therapy With Hydroxyurea and Interferon alfa Versus Cytarabine, Idarubicin, and Interferon alfa After Allogeneic Bone Marrow Transplantation in Patients With Chronic Phase Chronic Myelogenous Leukemia Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Other Protocol IDs: GER-CML-3, EU-95042, NCT00002771
14.	Phase III Randomized Study of Vaccination with Ganglioside GM2 Conjugated to Key Hole Limpet Hemocyanin plus Immunologic Adjuvant QS21 vs High Dose Interferon Alfa-2b in Patients with High Risk Melanoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: E-1694, CAN-NCIC-ME9, MDA-DM-E1694, MSKCC-96008, SWOG-9512, CAN-NCIC-E1694, MSKCC-E1694, SWOG-E1694, E1694, ME9
15.	Phase III Randomized Study of Adjuvant Interferon alfa in Stage IIIB Melanoma (Summary Last Modified 09/96) Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Protocol IDs: WHO-MEL-TRIAL16, EU-95046
16.	Phase III Randomized Study of Maintenance with Interferon alfa vs No Further Therapy Following Complete Response to Chemoradiotherapy for Small Cell Lung Cancer (Summary Last Modified 06/98) Phase: Phase III Type: Treatment Status: Closed Age: 18 to 74 Sponsor: Protocol IDs: FRE-Q93-902-02, EU-96008
17.	Combination Chemotherapy in Treating Patients With Lymphoma Phase: Phase III Type: Treatment Status: Completed Age: 15 to 59 Sponsor: NCI, Other Protocol IDs: MDA DM95-121, P30CA016672, NCI-V96-1010, CDR0000065044, NCT00002835
18.	Phase III Randomized Study of Interferon alfa With or Without Cytarabine Versus Autologous Peripheral Blood Stem Cell Transplantation Followed by Interferon alfa With or Without Cytarabine in Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (Summary Last Modified 03/2002) Phase: Phase III Type: Treatment Status: Completed Age: 15 to 65 Sponsor: NCI Protocol IDs: MRC-LEUK-CML-2000, ECOG-E7995, MRC-LEUK-CML-IV, MRC-LEUK-CML-IVa, EU-96029, NCT00002868, E7995
19.	Phase III Randomized Study of Low- vs High-Dose Interferon alfa for Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase Phase: Phase III Type: Treatment Status: Closed Age: adult Sponsor: Protocol IDs: MRC-LEUK-CML-V, EU-96028, NCT00002869
20.	Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma Phase: Phase III Type: Treatment Status: Completed Age: 10 to 70 Sponsor: NCI, Other Protocol IDs: ID95-196, P30CA016672, MDA-ID-95196, MDA-DM-95196, NCI-G96-1089, CDR0000065188, NCT00002882
21.	Phase III Randomized Study of Observation vs Adjuvant Low-Dose Extended-Duration Interferon alfa in Completely Resected Malignant Melanoma at High Risk of Recurrence (Summary Last Modified 04/2001) Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Protocol IDs: NCRI-AIM-HIGH, EU-96052, UKCCCR-AIM-HIGH, NCT00002892
22.	Phase III Study of Topical Therapy of Psoralen With Phototherapy (PUVA), Nitrogen Mustard (Mechlorethamine HCL) Chemotherapy, or Total Skin Electron Beam (TSE) Alone vs One Topical Therapy Combined With Interferon Alfa-2b for Cutaneous T-Cell Lymphoma (CTCL) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-1495, E1495
23.	Phase III Adjuvant Study of Levamisole vs Alfa Interferon 2a Plus Fluorouracil and Leucovorin Calcium for Intraperitoneal Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 75 and under Sponsor: Other Protocol IDs: CNR-TONE-01, EU-97011, NCT00003063
24.	Phase III Comparison Study of Subcutaneous Interferon Alfa-2b with or without Cytarabine After Cytoreduction with Hydroxyurea in Chronic Phase Chronic Myeloid Leukemia (Summary Last Modified 12/98) Phase: Phase III Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: CMLNSG-99, NCI-V97-1349
25.	Phase III Randomized Study of Chlorambucil Plus Dexamethasone With or Without Idarubicin Followed by Randomized Low Dose Interferon Alfa Versus Standard Dose Interferon Alfa Versus No Further Therapy in Patients with Stage II-IV Low Grade Non-Hodgkin's Lymphoma (Summary Last Modified 09/2000) Phase: Phase III Type: Treatment Status: Closed Age: 15 to 70 Sponsor: Protocol IDs: SNLG-NHL-VIII, EU-98034, NCT00003639